Physician profile
Lynn E Yonge
NPI 1235113861
$2,058.16
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $699 · 2020: $312 · 2021: $236 · 2022: $245 · 2023: $407 · 2024: $160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $567.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $566.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $444.49 | 2019-2022 | |
| Pfizer INC. | $299.30 | 2019-2023 | |
| Abbvie INC. | $177.82 | 2021-2023 | Vraylar |
| Astellas Pharma US INC | $115.34 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $108.29 | 2022-2024 | Rexulti, Nuedexta |
| Almatica Pharma LLC | $103.46 | 2023-2024 | Loreev Xr |
| Novo Nordisk INC | $98.99 | 2019-2024 | Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $93.68 | 2019-2022 | |
| Karyopharm Therapeutics INC. | $85.99 | 2021 | |
| Corium, LLC | $72.52 | 2023-2024 | Azstarys |
| Astrazeneca Pharmaceuticals Lp | $51.83 | 2019-2024 | Farxiga |
| Lilly USA, LLC | $49.43 | 2019-2021 | |
| Glaxosmithkline, LLC. | $41.22 | 2019-2022 | |
| Avanir Pharmaceuticals, INC. | $40.84 | 2019-2022 | |
| Neos Therapeutics, Lp | $39.12 | 2023 | Adzenys Xr-Odt |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $34.90 | 2021-2022 | |
| Tris Pharma INC | $34.76 | 2023 | Dyanavel Xr |
| Allergan, INC. | $24.96 | 2020 | |
| Medtronic, INC. | $22.25 | 2023 | Intellis Adaptivestim |
| Abbott Laboratories | $17.68 | 2023 | Freestyle Libre 2 |
| Amgen INC. | $17.22 | 2022 | |
| Adlon Therapeutics L.P. | $16.10 | 2020 | |
| Idorsia Pharmaceuticals US INC | $15.58 | 2023 | Quviviq |
| Exact Sciences Corporation | $15.08 | 2024 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $13.03 | 2020 | |
| Inogen, INC. | $12.58 | 2022 | |
| Shire North American Group INC | $11.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lynn Yonge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.